Vancouver-based MYND Life Sciences is exploring whether depression and other central nervous system disorders can be treated with novel psychedelic drugs, including psilocybin.
In January, the company announced a collaborative research agreement with the University of British Columbia on major depressive disorder.
“We have an opportunity to improve the wellness and quality of life of people suffering from depression, anxiety and addiction and this agreement helps set the foundation for the development of novel therapies utilizing psilocybin and other related compounds,” said Dr. Lyle Oberg, MYND’s chief executive officer.
MYND is now one step closer to that goal after signing a licensing agreement with private vaccine developer Eyam.
The Letter of Intent, announced last month, gives MYND an exclusive license with respect to Eyam’s proprietary technologies for applications to central nervous system vaccines.
This agreement with Eyam will allow MYND to access yet another cutting edge technology with the development of vaccines that have the ability to prevent neurological disorders such as major depressive disorder, by stopping the neuro-inflammatory process before it starts,” explains Dr. Oberg.
MYND is working to develop a suite of central nervous system disorder treatment protocols, including diagnostic capacity with blood markers, treatment with specific psilocybin and other psychedelic analogs, and immunoprotection.
The company is also working on methods for treating or delaying Alzheimer’s disease and related forms of dementia.
“Diagnosing, preventing and treating diseases of the central nervous system is at the core of our focused corporate strategy,” Dr. Oberg said last month. “Alzheimer’s disease affects millions of people around the globe and remains a catastrophic condition without a cure.”
Subscribe to Weekend Dispensary, a new weekly newsletter from The GrowthOp.